Recommendations for the management of tyrosinaemia type 1

Corinne de Laet; Carlo Dionisi-Vici; James V. Leonard; Patrick McKiernan; Grant Mitchell; Lidia Monti; H. Ogierélène de Baulny; Guillem Pintos-Morell; Ute Spiekerkötter

doi:10.1186/1750-1172-8-8

Recommendations for the management of tyrosinaemia type 1

Corinne de Laet, Carlo Dionisi-Vici, James V. Leonard, Patrick McKiernan, Grant Mitchell, Lidia Monti, H. Ogierélène de Baulny, Guillem Pintos-Morell, Ute Spiekerkötter

Ospedale Pediatrico Bambino Gesu

Research output: Contribution to journal › Article › peer-review

Abstract

The management of tyrosinaemia type 1 (HT1, fumarylacetoacetase deficiency) has been revolutionised by the introduction of nitisinone but dietary treatment remains essential and the management is not easy. In this review detailed recommendations for the management are made based on expert opinion, published case reports and investigational studies as the evidence base is limited and there are no prospective controlled studies.The added value of this paper is that it summarises in detail current clinical knowledge about HT1 and makes recommendations for the management.

Original language	English
Pages (from-to)	8
Number of pages	1
Journal	Orphanet Journal of Rare Diseases
DOIs	https://doi.org/10.1186/1750-1172-8-8
Publication status	Accepted/In press - Jan 11 2013

ASJC Scopus subject areas

Pharmacology (medical)
Genetics(clinical)
Medicine(all)

Access to Document

10.1186/1750-1172-8-8

Fingerprint Dive into the research topics of 'Recommendations for the management of tyrosinaemia type 1'. Together they form a unique fingerprint.

Cite this

@article{a36416f46c094e4b810c6ec7a670ac42,

title = "Recommendations for the management of tyrosinaemia type 1",

abstract = "The management of tyrosinaemia type 1 (HT1, fumarylacetoacetase deficiency) has been revolutionised by the introduction of nitisinone but dietary treatment remains essential and the management is not easy. In this review detailed recommendations for the management are made based on expert opinion, published case reports and investigational studies as the evidence base is limited and there are no prospective controlled studies.The added value of this paper is that it summarises in detail current clinical knowledge about HT1 and makes recommendations for the management.",

author = "{de Laet}, Corinne and Carlo Dionisi-Vici and Leonard, {James V.} and Patrick McKiernan and Grant Mitchell and Lidia Monti and {de Baulny}, {H. Ogier{\'e}l{\`e}ne} and Guillem Pintos-Morell and Ute Spiekerk{\"o}tter",

year = "2013",

month = jan,

day = "11",

doi = "10.1186/1750-1172-8-8",

language = "English",

pages = "8",

journal = "Orphanet Journal of Rare Diseases",

issn = "1750-1172",

publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Recommendations for the management of tyrosinaemia type 1

AU - de Laet, Corinne

AU - Dionisi-Vici, Carlo

AU - Leonard, James V.

AU - McKiernan, Patrick

AU - Mitchell, Grant

AU - Monti, Lidia

AU - de Baulny, H. Ogierélène

AU - Pintos-Morell, Guillem

AU - Spiekerkötter, Ute

PY - 2013/1/11

Y1 - 2013/1/11

N2 - The management of tyrosinaemia type 1 (HT1, fumarylacetoacetase deficiency) has been revolutionised by the introduction of nitisinone but dietary treatment remains essential and the management is not easy. In this review detailed recommendations for the management are made based on expert opinion, published case reports and investigational studies as the evidence base is limited and there are no prospective controlled studies.The added value of this paper is that it summarises in detail current clinical knowledge about HT1 and makes recommendations for the management.

AB - The management of tyrosinaemia type 1 (HT1, fumarylacetoacetase deficiency) has been revolutionised by the introduction of nitisinone but dietary treatment remains essential and the management is not easy. In this review detailed recommendations for the management are made based on expert opinion, published case reports and investigational studies as the evidence base is limited and there are no prospective controlled studies.The added value of this paper is that it summarises in detail current clinical knowledge about HT1 and makes recommendations for the management.

UR - http://www.scopus.com/inward/record.url?scp=84872137635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872137635&partnerID=8YFLogxK

U2 - 10.1186/1750-1172-8-8

DO - 10.1186/1750-1172-8-8

M3 - Article

C2 - 23311542

AN - SCOPUS:84872137635

SP - 8

JO - Orphanet Journal of Rare Diseases

JF - Orphanet Journal of Rare Diseases

SN - 1750-1172

ER -